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Edited by Lukas HuberAbstract The present study shows that the IFN-c-mediated
upregulation of secretory phospholipase A2 of group IIA
(sPLA2-IIA) in HASMC and HepG2 cells is synergistically
increased after simultaneous inhibition of glycogen synthase
kinase-3b (GSK-3b) by indirubin-30-monoxime, 5-iodo or AR-
A014418. The eﬀect of GSK-3b inhibition was dose- and time-
dependent and can be further augmented by its concomitant
incubation with Clostridium diﬃcile toxin B, an inhibitor of
small Rho proteins, or H-1152, an inhibitor of Rho-associated
kinase. Using AG-490 and caﬀeic acid phenethyl ester (CAPE),
it is further demonstrated that the eﬀect of GSK-3b inhibition on
sPLA2-IIA expression depends on Janus kinase-2 and NF-jB-
signaling.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The secretory group IIA phospholipase A2 is constitutively
expressed in a number of mammalian cell types and tissues.
In hepatic, endothelial, mesangial, and smooth muscle cells,
secretory phospholipase A2 of group IIA (sPLA2-IIA) is in-
duced in vitro upon stimulation with proinﬂammatory cyto-
kines (for review [1]). Increased serum activities of this
enzyme can be observed in severe acute inﬂammatory dis-
eases such as sepsis, septic shock [2,3], acute pancreatitis [4],
and multiple injuries [5,6]. The origin of the serum sPLA2-* Corresponding author. Fax: +49-351-458-4332.
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interferon-c; Jak, Janus tyrosine kinase; MEK, mitogen-activated
protein kinase; NF-jB, nuclear factor-kappa B; RT-PCR, reverse
transcription-polymerase chain reaction; sPLA2-IIA, secretory phos-
pholipase A2 of group IIA; STAT, signal transducer and activator of
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with activated leukocytes, smooth muscle cells and the liver
come particularly into question as a locale for synthesis [7].
The detailed function of the raising sPLA2-IIA levels in se-
rum during inﬂammation is also still unspeciﬁed. Similar to
other phospholipases A2, sPLA2-IIA may be involved in cell
signaling, apoptosis, remodeling of cell membranes, inﬂam-
matory response, and host defense against bacterial invaders
(for review [8,9]). Apart from direct eﬀects through phos-
pholipolysis, sPLA2-IIA can also elicit proinﬂammatory
changes in an autocrine manner by the induction of tumor
necrosis factor-receptor superfamily signaling and activation
of MAP kinase cascade [10,11]. Thus, the knowledge of
mechanisms regulating the expression of sPLA2-IIA is of
special importance.
It is established that the expression of sPLA2-IIA is cell-
and species-speciﬁc [1,12] and depends on the activity of
cellular signaling pathways and transcription factors such as
nuclear factor-kappa B (NF-jB), CCAAT box enhancer
binding proteins (C/EBP), Janus tyrosine kinase (Jak)/signal
transducer and activator of transcription (STAT), phospha-
tidylinositol-3-kinase-Akt, peroxisome proliferator-activated
receptor, protein kinase C, cAMP/protein kinase A, and
mitogen-activated protein kinase (MEK)/extracellular signal-
regulated kinase (ERK) [13–17]. Recently, it was shown that
interleukin-1b (IL-1b)-stimulated sPLA2-IIA expression in
rat mesanglial cells is negatively controlled by RhoA/Rho-
kinase pathways [18]. We have also observed a similar
negative control of interferon-c (IFN-c)-mediated sPLA2-IIA
expression through RhoA/Rho-kinase and Ras/Raf/MEK/
ERK pathways in human aortic smooth muscle cells
(HASMC) and HepG2 (submitted for publication).
In the present study, we pursued the question to what
extent glycogen synthase kinase-3b (GSK-3b) is involved in
this negative regulation of sPLA2-IIA expression. It is
known that the activity of GSK-3b is increased after Tyr-
216 phosphorylation through RhoA/Rho-kinase [19] and
MEK1/2 signaling [20]. We demonstrate for the ﬁrst time
that the activity of GSK-3b is important in the regulation of
sPLA2-IIA and that inhibition of GSK-3b results in a po-
tentiation of IFN-c-induced sPLA2-IIA expression in
HASMC and HepG2 cells via processes which are Jak2 and
NF-jB-dependent.blished by Elsevier B.V. All rights reserved.
Fig. 1. Upregulation of sPLA2-IIA mRNA in HASMC by indirubin-
30-monoxime,5-iodo (indirubin). After exposure of HASMC for 48 h
to indirubin and IFN-c, both alone and in combination, the sPLA2-
IIA mRNA in relation to GAPDH mRNA was determined by
RT-PCR. Agarose gel electrophoresis with ethidium bromide-stained
ampliﬁcates is shown. M indicates 100 bp molecular weight ladder;
lane 1, control; lane 2, 50 nM indirubin; lane 3, 25 ng/ml IFN-c; lane 4,
50 nM indirubin and 25 ng/ml IFN-c.
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2.1. Materials
Recombinant human IFN-c was purchased from R&D Systems
GmbH (Wiesbaden-Nordenstadt, Germany). Clostridium diﬃcile
toxin B (TcdB), indirubin-30-monoxime, 5-iodo-, AR-A014418 (N-(4-
methoxybenzyl)-N0-(5-nitro-1,3-thiazol-2-yl)urea), AG-490 (Tyrpho-
stinB42), and H-1152 ((S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)-
sulfonyl]homopiperazine, 2HCl) were from Calbiochem (San Diego,
California, USA). Caﬀeic acid phenethyl ester (CAPE) was pur-
chased from Sigma–Aldrich. Polyclonal rabbit antibodies against
sPLA2-IIA were obtained from Cayman Chemical (MI, USA). AR-
A014418, indirubin-30-monoxime, 5-iodo-, AG-490, and CAPE were
dissolved in dimethyl sulfoxide (DMSO). The ﬁnal concentrations of
solvents were 0.3% or less. Controls using DMSO alone were run in
all cases.
2.2. Cell culture and incubation
HASMC were purchased from Promocell (Heidelberg, Germany)
and cultured according to the instructions in smooth muscle cell
growth medium-2 at 37 C in a humidiﬁed atmosphere of 5% CO2. The
human HepG2 hepatoma cell line was obtained from American Type
Culture Collection (Rockville, Maryland, USA) and maintained in
RPMI supplemented with 10% fetal calf serum (FCS) and cultured
under the same condition as described for HASMC.
For RNA isolation and determination of sPLA2-IIA protein in
cells released into the media, cells were plated onto 6-well and 24-
well plates at a cell density of 104 cells/cm2. For all experiments,
exponentially growing subconﬂuent HASMC and conﬂuent HepG2
cells were used at passages 5–8. At the end of the incubation period,
media were removed, centrifuged with 800 g for 10 min to remove
cell debris, and kept at )80 C until analysis for sPLA2-IIA con-
centration. The attached cells were lysed in TRI Reagent (Sigma–
Aldrich, Deisenhofen, Germany) and stored at )80 C until RNA
isolation or lysed in cell lysis buﬀer (Promega) after washing with
phosphate-buﬀered saline and stored at )80 C until analysis for
sPLA2-IIA content.
2.3. RNA extraction and reverse transcriptase-polymerase chain
reaction (RT-PCR) analysis
RNA was isolated after lysis of cells in TRI reagent according to
the manufacturer’s instructions. Isolated RNA was converted to
cDNA by using the GeneAmp RNA-PCR Kit (Perkin–Elmer). A
portion of the RT reaction products was then ampliﬁed for identi-
ﬁcation of sPLA2-IIA and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) as house-keeping gene using PCR. The applied
primer pairs were 50-GTGATCATGATCTTTGGCCTACTGCA-30
and 50-TCTCCCTCGTGGGGAGCAACGACT-30 for sPLA2-IIA,
giving PCR products with a length of 411 bp, and 50-CGGAGT-
CAACGGATTTGGTCGTATTG-30 and 50-GCAGGAGGCATTG-
C-TGATGATCTTG-30 for GAPDH amplifying products with 439
bp length. The oligonucleotides for the analysis of sPLA2-IIA
mRNA were synthesized according to the published nucleotide se-
quence of human placental sPLA2-IIA cDNA [21] and for GAPDH-
mRNA according to the published nucleotide sequence [22].
2.4. Quantitative determination of sPLA2-IIA by ELISA
The sPLA2-IIA protein in cells released into the medium was de-
termined using speciﬁc enzyme-linked immunosorbent assay (ELISA)
kits according to the manufacturer’s instructions (Cayman Chemical,
MI). Total cell protein was determined by using Bicinchoninic Acid
assay kit with bovine serum albumin as internal standard (Sigma–
Aldrich).
2.5. Western blot analysis
Aliquots of the medium were incubated with Laemmli buﬀer at 95
C for 5 min and the proteins were separated by 7.5%ic SDS poly-
acrylamide gel electrophoresis. After transferring of proteins to ni-
trocellulose membranes by electroblotting, the membranes were
incubated with a speciﬁc polyclonal rabbit anti-sPLA2-IIA antiserum
overnight at 4 C. After washing, the nitrocellulose membranes were
incubated with horseradish peroxidase-labeled anti-rabbit IgG for 1 h
at room temperature. The sPLA2-IIA protein was visualized by en-
hanced chemiluminescence using the ECL system (Amersham Phar-
macia Biotech, Freiburg, Germany).3. Results
3.1. Upregulation of sPLA2-IIA expression in HASMC by
GSK-3b inhibition
Fig. 1 shows the eﬀect of indirubin-30-monoxime,5-iodo (50
nM) alone and in combination with IFN-c (25 ng/ml) on the
level of sPLA2-IIA mRNA in HASMC. Here, after incubation
of the cells with both IFN-c and indirubin, an increase of
sPLA2-IIA mRNA could be observed (Fig. 1, lanes 2 and 3).
When both agents were added simultaneously to the cell me-
dium, a further increase in sPLA2-IIA mRNA was the result
(Fig. 1, lane 4). These data agreed with the sPLA2-IIA protein
quantities secreted from the HASMC into the medium and
obtained by ELISA. Thus, in comparison to the control cells
the sPLA2-IIA secretion increased 4-fold after incubation for
48 h with 25 ng/ml IFN-c and 3-fold with 50 nM indirubin
(Fig. 2). When indirubin was introduced in combination with
IFN-c in equal concentrations, the secretion of sPLA2-IIA
increased 25-fold, indicating a synergistic eﬀect of both com-
ponents. A similar synergism arose, albeit not as pronounced,
between IFN-c and AR-A014418 as well (Fig. 2). When the
cells were stimulated with 10 ng/ml TcdB as an inhibitor of the
Rho proteins and 25 ng/ml IFN-c, the sPLA2-IIA secretion
climbed to a level 20 times that of the control cells. The
combination of TcdB (10 ng/ml) and IFN-c (25 ng/ml) with
indirubin (50nM) led ﬁnally to an increase in sPLA2-IIA
secretion of more than 100 times. In this instance, the increase
was dependent on the concentration of indirubin (Fig. 2). In
this fashion, the sPLA2-IIA protein secretion increased to
approximately 4–15 times that of the control cells when in-
dirubin in concentrations ranging from 12.5 to 200 nM was
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Fig. 2. Dose-dependent increase of sPLA2-IIA secretion in HASMC by
GSK-3b inhibitors, indirubin and AR-A014418, alone and in combi-
nation with IFN-c and TcdB. After exposure of cells to GSK-3b in-
hibitors in varied concentrations for 48 h in the absence or presence of
25 ng/ml IFN-c and 10 ng/ml TcdB, the sPLA2-IIA protein released
into the medium was determined. Results are means S.D. of three
samples per experiment and are representatives of three independent
experiments.
M. Menschikowski et al. / FEBS Letters 577 (2004) 81–86 83introduced into the cell medium simultaneously with 10 ng/ml
TcdB (Fig. 2). A 40- to 120-fold increase in comparison to the
control cells resulted when, along with indirubin (12.5–200.0
nM) and 10 ng/ml TcdB, 25 ng/ml IFN-c was added simulta-
neously (Fig. 2). A similar, concentration-dependent increase
could be observed following incubation of the cells with AR-
A014418. Along with the dependence on concentration, the
eﬀects of indirubin were time-dependent (Fig. 3). Similar re-
sults apply to AR-A014418 (data not shown).
3.2. Upregulation of sPLA2-IIA expression in HepG2 cells by
GSK-3b inhibition
To verify the cell speciﬁcity of GSK-3b-dependent sPLA2-
IIA upregulation, human HepG2 hepatoma cells were ex-
posed to indirubin alone and in the presence of 25 ng/ml0
100
200
300
400
500
IFN-γ
Ind
Ind+IFN-γ
TcdB+IFN-γ
Ind+TcdB+IFN-γ
s
PL
A 2
-
IIA
 
re
le
as
e
(pg
/m
g c
el
l p
ro
te
in
)
48h24h17h
Fig. 3. Time course of sPLA2-IIA secretion in HASMC incubated with
indirubin alone and in combination with IFN-c and TcdB. After
treatment of HASMC for 17–48 h with 50 nM indirubin in the absence
or presence of 25 ng/ml IFN-c and 10 ng/ml TcdB, the sPLA2-IIA
protein released into the cell medium was determined. Results are
meansS.D. of three samples per experiment and are representatives
of three independent experiments.IFN-c or in combination with H-1152, a Rho-kinase inhibi-
tor (Fig. 4). Similar to the HASMC, a signiﬁcant upregula-
tion of sPLA2-IIA expression in HepG2 cells was observed
by stimulation with IFN-c. The incubation of the cells with
H-1152 also led to a signiﬁcant increase in sPLA2-IIA se-
cretion, while incubation with indirubin alone produced only
a minimal increase. When indirubin was combined with IFN-
c, the sPLA2-IIA secretion rates increased signiﬁcantly, in-
deed to a lesser extent when compared to those observed
after incubation of HASMC with indirubin and IFN-c. The
lower observed level of sPLA2-IIA induction could possibly
be explained by the relatively high basal level of sPLA2-IIA
secretion of HepG2 cells, which was approximately 800 times
as high as those of HASMC. The strongest increase in
sPLA2-IIA secretion was reached when the HepG2 cells were
incubated simultaneously with indirubin, H-1152, and IFN-c
(Fig. 4).
3.3. Inhibition of Jak2/STAT and NF-jB signaling prevents
sPLA2-IIA upregulation in HASMC and HepG2 cells
In an earlier study, we found that in the negative regulation
of sPLA2-IIA expression through RhoA/Rho-kinase and Ras/
Raf/MEK/ERK pathways, Jak2- and NF-jB-dependent
pathways play a signiﬁcant role. Thus, we applied inhibitors
of Jak2- (AG-490) and NF-jB-signaling (CAPE) to examine
whether these pathways could also be involved in the GSK-
3b-controlled expression of sPLA2-IIA. Here, it could be
shown that both AG-490 and CAPE were able to reduce the
level of sPLA2-IIA transcripts and to block almost com-
pletely the synthesis and secretion of sPLA2-IIA in HASMC,
induced through incubation with (i) indirubin and IFN-c
alone; (ii) indirubin and IFN-c in combination with TcdB;
and (iii) AR-A014418, IFN-c, and TcdB (Fig. 5). Similar
results were obtained after adding pyrrolidine dithiocarba-
mate (PTDC) and 20 S Proteasome inhibitor I (PSI) as fur-
ther inhibitors of NF-jB-signaling and in HepG2 cells
(results not shown).4. Discussion
To our knowledge, this is the ﬁrst report showing the im-
portance of GSK-3b activity in the regulation of sPLA2-IIA
expression in HASMC and HepG2 cells. Indeed, sPLA2-IIA
expression either remained unchanged or increased only
slightly as a result of the inhibition of GSK-3b alone.
However, a large increase in sPLA2-IIA expression could be
demonstrated when IFN-c was simultaneously introduced
into the cell medium. Various GSK-3b inhibitors are known
and have been used as a tool in a great number of studies to
illuminate the role of this kinase in cellular signaling, physi-
ological events, and diﬀerent diseases. In this study, two
structurally distinct GSK-3b inhibitors were applied. Indiru-
bin-30-monoxime,5-iodo is characterized by IC50 10 nM
toward GSK-3b; however, like other substituted indirubins it
inhibits as well the activity of cyclin-dependent kinases
(CDK) [23]. AR-A014418, another speciﬁc inhibitor of GSK-
3b, is a member of the family of thiazol derivatives and is
considered to be the ﬁrst known compound that does not
signiﬁcantly inhibit the activity of CDK2 or CDK5 [24]. For
these reasons, along with indirubin, we applied AR-A014418
as GSK-3b inhibitor in this study. Thus, it could be shown
Fig. 4. Stimulation of sPLA2-IIA secretion after exposure of human HepG2 cells to indirubin alone and in combination with IFN-c and Rho-kinase
inhibitor, H-1152 for 48 h. (A) Immunoblot showing the released sPLA2-IIA protein by using polyclonal anti-sPLA2-IIA antiserum, 30 lg of protein
was applied per lane. (B) Quantiﬁcation of released sPLA2-IIA protein using the ELISA technique. Results are meansS.D. of analysis in triplicate
and are representatives of three independent experiments.
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using AR-A014418.
The proof of a role of GSK-3b in the regulation of sPLA2-
IIA is of special interest because several transcription factors
important to the regulation of sPLA2-IIA serve as substrates
for GSK-3b. Among these, for example, is the transcription
factor NF-jB, whose function is strikingly altered by GSK-3b
[25–27]. The extent to which GSK-3b activates or blocks NF-
jB signaling is the subject of some discussion (for review [28]).
On the one hand, studies with mice lacking GSK-3b have
suggested that GSK-3b is required for NF-jB activation [29].
On the other hand, several new studies provided evidence for
an inverse association between the activity of GSK-3b and
NF-jB signaling. For example, Rao et al. [30] have recently
shown that in renal medullary interstitial cells the expression of
cyclooxygenase-2 (COX-2) is negatively regulated by GSK-3b,
in that the inhibition of GSK-3b leads to an activation of
COX-2 via induction of NF-jB-dependent pathways. Sanchez
et al. [31] described in their study that an overexpression of
GSK-3b in astrocytes is associated with the inhibition of
NF-jB activation. This was due to a stabilization of the NF-
jB-inhibitory protein, IjBa, and a downward regulation of
IjB kinase activity. Furthermore, Bournat et al. [32] and Ne-
meth et al. [33] found that lithium which inhibits GSK-3b has
increased the NF-jB activity in the rat pheochromocytoma cell
line PC12 and human intestinal epithelial cells, respectively.
The reason for apparent discrepancy in modulatory eﬀects of
GSK-3b on NF-jB activity remains to be resolved. In the
present study, it could be shown that inhibitors of NF-jB
(CAPE, PTDC, and PSI) and of Jak2 (AG-490) completelyobviate an increase in sPLA2-IIA synthesis and secretion
caused by GSK-3b inhibitors. This leads to the conclusion that
both the NF-jB and Jak2/STAT pathways take part in the
upward regulation of sPLA2-IIA expression triggered by the
inhibitors of GSK-3b.
If the RhoA/Rho-kinase pathway is inhibited as well as that
of GSK-3b, this leads to a synergistic sPLA2-IIA increase
following the separate inhibiting of both pathways. An ex-
planation for this ampliﬁcation could be that GSK-3b is ac-
tivated upstream by the RhoA/Rho-kinase pathway, as
described by Sayas et al. [19]. In this connection, it is re-
markable that the inhibition caused by Jak2 alone or by NF-
jB alone completely hindered the synergistic eﬀect of IFN-c,
GSK-3b, and RhoA/Rho-kinase inhibitors, which leads to the
conclusion that for the optimal induction of sPLA2-IIA ex-
pression both, e.g., Jak2- and NF-jB-dependent, signaling
pathways must be equally active.
The inhibition of GSK-3b activity by low-molecular nat-
ural or artiﬁcial substances is believed to be variously ben-
eﬁcial, for example, in the treatment of neurodegenerative
diseases, diabetes type II, bipolar disorders, stroke, cancer,
and chronic inﬂammatory disease (for review [34]). To the
extent that some of these beneﬁcial eﬀects stand in con-
junction with sPLA2-IIA induction described here bears
further study. It is, however, known that an overexpression
of GSK-3b goes hand-in-hand with an ampliﬁed apoptosis
and, vice versa, that inhibitors provide protection from ap-
optosis caused by hyperactive GSK-3b [35]. The mechanism
behind this is as yet unexplained. In this connection, it is
remarkable that anti-apoptotic properties have been ascribed
Fig. 5. Eﬀects of Jak2 inhibitor, AG490, and NF-jB inhibitor, CAPE,
on the indirubin-, AR-A014418-, and TcdB-mediated upregulation of
the sPLA2-IIA in the presence of IFN-c (25 ng/ml) in HASMC. Cells
were incubated for 48 h with indicated additions. (A) sPLA2-IIA
mRNA in relation to GAPDH mRNA after RT-PCR in the agarose
gel electrophoresis. M indicates 100 bp molecular weight ladder.
(B) Quantiﬁcation of the cell-associated sPLA2-IIA protein. (C)
Quantiﬁcation of the cellular sPLA2-IIA protein released using the
ELISA technique, respectively. Results are meansS.D. of analysis in
triplicate and are representatives of three independent experiments.
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sion by inhibition of GSK-3b coincides with that, which
could be a possible cause of minimized apoptosis.
In conclusion, the study demonstrates that the GSK-3b
takes part in a negative regulation of sPLA2-IIA expression.
Thus, the inhibition of the GSK-3b alone and especially in
combination with the RhoA/Rho-kinase pathway leads to a
markedly increased synthesis and secretion of sPLA2-IIA when
HASMC and HepG2 cells are simultaneously stimulated with
IFN-c. The mechanism of the negative regulation seems to
have as its basis the inhibition of the Jak/STAT- and NF-jB-
dependent signaling pathways, in that by means of the inhi-
bition of Jak2 and/or NF-jB the inductive eﬀect of GSK-3b
and RhoA/Rho-kinase inhibitors on the IFN-c-mediatedsPLA2-IIA upregulation is nulliﬁed. The physiological rele-
vance of this observation is reserved for further studies, which
ﬁrst will investigate the function of sPLA2-IIA during
inﬂammation.
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